An option for low-risk prostate cancer
"With active surveillance, we continue to monitor the cancer very closely to get a grasp on its behavior before committing to treatment," says Dr. Marc Garnick, a prostate cancer specialist at Harvard Medical School and Beth Israel Deaconess Medical Center. "For many men, active surveillance makes more sense than immediate treatment. It allows them to avoid the potential harms and uncertain benefits of treating a low-risk cancer."
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
